Blow for sufferers as experimental Alzheimer's drug is scrapped
Studies of one of the most anticipated experimental drugs for Alzheimer's disease have been scrapped after it failed to help patients with the condition in a high-profile clinical trial.
Pfizer Inc and Johnson & Johnson said they would discontinue all other studies of the drug bapineuzumab including two more trials and follow-up extension studies, in patients with mild-to-moderate Alzheimer's.
The result marked the second such late-stage failure announced in recent weeks and was especially disappointing as bapineuzumab had been given a better chance of success in the patients studied in the second trial. If successful, it would have been the first drug to fight the progression of the debilitating brain disease.
Attention will now turn to solanezumab, a similar drug being developed by Eli Lilly & Co that is also considered a long-shot to succeed, but will still carry fading hopes at least until test results are released later this year. Shares in all three drugs firms fell following news of the latest disappointment.
Any successful Alzheimer's treatment is likely to reap many billions of pounds in sales, and industry analysts said many investors were holding shares in the companies in case the drugs were to succeed. "We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer's disease," said Steven Romano, head of Pfizer's medicines development group.
Life & Style blogs
Plus live in a folly tower and Towcester growth
Plus how much you need to earn to rent in London, and new homes figures
Plus where The Apprentices live, house price growth outside London, and househunter numbers
- 1 Heading for the States? Prepare for the longest US immigration queues ever
- 2 Amir Khan interview: 'One second could end my boxing career'
- 3 Boxing: Purdy set to join long list of British fighters who take the money – and then the beating
- 4 Dan Stevens after Downton Abbey: The erstwhile Matthew Crawley is back in period costume
- 5 Join Ryanair! See the world! But we'll only pay you for nine months a year
BMF is the UK’s biggest and best loved outdoor fitness classes
Find out what The Independent's resident travel expert has to say about one of the most beautiful small cities in the world
Win anything from gadgets to five-star holidays on our competitions and offers page.
£30000 - £40000 per annum + BENS: Progressive Recruitment: Drupal Developer A ...
£45000 - £50000 per annum + bens: Progressive Recruitment: C# WEB DEVELOPER Le...
£240 - £260 per day: Progressive Recruitment: WPF Developer (C#, VB.Net) North...
£85 - £120 per day: Randstad Education Cheshire: KS2 teacher needed to do PPA ...